Posted On: 10/09/2015 5:06:07 PM
Post# of 72447
Planned Kevetrin trials:
1. Ovarian – single agent and in combo, phase 2, orphan status
2. Pancreatic – single agent, phase 2, orphan status and research grant applied
3. AML – single agent and in combo with cytarabine, phase 2, paid for by University of Bologna
4. Renal – in combo with a tyronsine kinase inhibitor, phase 2, possible Specialized Programs of Research Excellence (SPORE) grant
5. Retinoblastoma – single agent, phase 2, possible Pediatric Disease Priority Review Voucher (PPRV)
1. Ovarian – single agent and in combo, phase 2, orphan status
2. Pancreatic – single agent, phase 2, orphan status and research grant applied
3. AML – single agent and in combo with cytarabine, phase 2, paid for by University of Bologna
4. Renal – in combo with a tyronsine kinase inhibitor, phase 2, possible Specialized Programs of Research Excellence (SPORE) grant
5. Retinoblastoma – single agent, phase 2, possible Pediatric Disease Priority Review Voucher (PPRV)
(0)
(0)
